Patents Examined by Ibrahim D Bori
  • Highly concentrated stable meloxicam solutions
    Patent number: 9993557
    Abstract: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The formulation according to the invention has a shelf-life of up to 24 months or more.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: June 12, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Stefan Henke, Bernd Kruss, Bernhard Hassel, Hans-Jurgen Kroff, Martin A. Folger, Klaus Daneck, Axel Prox
  • Pyrimidine derivatives as CFTR modulators
    Patent number: 9981945
    Abstract: A compound having the structure of Formula II, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof: The compound is useful as CFTR modulator. Further, a method of using the compound and pharmaceutical composition comprising the compound are provided for treating diseases in lungs, pancreas, gastrointestinal system, sinuses, reproductive system, and the sweat glands.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: May 29, 2018
    Assignee: NuBridge BioSciences
    Inventors: Lin Zhang, Yu Ge
  • Composition for exterminating scuticociliates in fish including mebendazole
    Patent number: 9956204
    Abstract: The present disclosure relates to a composition for exterminating scuticociliates in fish, comprising Mebendazole as an active ingredient, and to a method for exterminating scuticociliates by performing oral administration or immersion administration of Mebendazole in fish. According to the present disclosure, the composition and the extermination method have excellent effects in exterminating scuticociliates in fish, and can be efficiently used in the aquaculture industry by performing oral administration or immersion administration.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 1, 2018
    Assignee: NATIONAL INSTITUTE OF FISHERIES SCIENCE
    Inventors: Jung Soo Seo, Na Young Kim, Sung-hee Jung, Myoung Sug Kim
  • Highly concentrated stable meloxicam solutions
    Patent number: 9956288
    Abstract: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The solution is for treating a mammal suffering from one or more of pain, inflammation, fever, acute mastitis, diarrhea, lameness, locomotor deficiency, or respiratory illness.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: May 1, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Stefan Henke, Bernd Kruss, Bernhard Hassel, Hans-Juergen Kroff, Martin A. Folger, Klaus Daneck, Axel Prox
  • N,N?-diarylurea compounds and N,N?-diarylthiourea compounds as inhibitors of translation initiation
    Patent number: 9932300
    Abstract: Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N?-diarylureas and/or N,N?-diarylthiourea compounds are described.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 3, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: Bertal Huseyin Aktas, José A. Halperin, Michael Chorev
  • Chlorogenic acid powder-injection and preparation method thereof
    Patent number: 9918956
    Abstract: The present invention provides a chlorogenic acid powder-injection. The chlorogenic acid powder-injection is prepared from the following raw materials in parts by weight: 1-120 parts of chlorogenic acid, 1-320 parts of a bracket agent and 1-8 parts of an antioxidant. The present invention further provides a preparation method of the powder-injection. The chlorogenic acid powder-injection provided in the present invention is good in stability, strong in re-solubility and safe in clinical use.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: March 20, 2018
    Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD
    Inventors: Jie Zhang, Huarong Yang, Chenxu Tian, Yongjiang Yan, Lina Zhu, Wang Huang
  • Microbial product having antifungal activity
    Patent number: 9896457
    Abstract: Provided are a compound having a novel mother nucleus, which can be a promising drug discovery seed compound, use thereof as an antifungal agent, and a production method thereof and the like. A compound represented by the following formula: or a pharmaceutically acceptable salt thereof, and an antifungal agent containing same, and the like.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: February 20, 2018
    Assignees: OP Bio Factory Co., Ltd., Seed Research Institute Co., Ltd.
    Inventors: Morita Iwami, Sachi Kato, Yoshimi Matsumoto, Hideo Naoki
  • Fluorinated benzofuran derivatives
    Patent number: 9895340
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 20, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • Filler composition for the treatment of lipoatrophy
    Patent number: 9884138
    Abstract: The present invention refers to a composition that is useful as a filler for the correction of soft tissue volume loss, for example for the cosmetic treatment of wrinkles, or for the treatment of disorders such as lipoatrophy or lipodystrophy in general, said composition comprising agarose and hyaluronic acid, or a pharmaceutically acceptable salt thereof. The particular interaction that takes place between the two components makes even high concentrations of agarose injectable and tolerable, said high concentrations being particularly useful for ensuring the duration and stability over time of the aesthetic results that are achievable using this filler.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 6, 2018
    Assignee: Advanced Aesthetic Technologies, Inc.
    Inventor: Mauro Matteuzzi
  • Anticoagulant reversal agents
    Patent number: 9877961
    Abstract: Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: January 30, 2018
    Assignee: PEROSPHERE INC.
    Inventors: Solomon S. Steiner, Bryan E. Laulicht, Sasha H. Bakhru, Edith Mathiowitz
  • PDE1 inhibitor
    Patent number: 9868741
    Abstract: The present invention provides a compound of Formula I: useful for treating chronic kidney disease and diabetic kidney disease.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 16, 2018
    Assignee: Eli Lilly and Company
    Inventor: Cynthia Darshini Jesudason
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 9850229
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 26, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 9850230
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 26, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same
    Patent number: 9828622
    Abstract: The present invention provides photosensitizer compounds for use in detecting beta-lactamase activity. Methods and kits that utilize the photosensitizer compounds of the invention for the detection of, quantitation of, and classification or typing of microbial beta-lactamases.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: November 28, 2017
    Assignee: The General Hospital Corporation
    Inventors: Tayyaba Hasan, Ulysses W. Sallum, Sarika Verma, Gerard Nau
  • Small molecule securinine and norsecurinine analogs and their use in cancers, inflammatory diseases and infections
    Patent number: 9827229
    Abstract: The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 28, 2017
    Assignee: INVENIO THERAPEUTICS INC.
    Inventors: Mahesh K. Gundluru, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, David Wald
  • Prodrugs of non-steroid anti-inflammatory agents (NSAIDS)
    Patent number: 9809557
    Abstract: The present invention relates to novel depot formulations (prodrugs) comprising an immobility promoting unit linked via an ester to an active pharmaceutical ingredient, i.a. common NSAIDs. The novel depot formulations are suitable for intra-articular injections and are soluble at slightly acidic pH to facilitate ease of injection, and sparingly soluble at physiological pH thereby precipitating at the site of administration. The precipitate will slowly dissolve and the active drug is released from dissolved depot formulation following esterase mediated cleavage of the ester link between the immobility promoting unit and the active pharmaceutical agent.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: November 7, 2017
    Inventor: Claus Selch Larsen
  • Coferons and methods of making and using them
    Patent number: 9771345
    Abstract: The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 ?M and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: September 26, 2017
    Assignees: Cornell University, Purdue Research Foundation, BlinkBio, Inc.
    Inventors: Francis Barany, Maneesh Pingle, Sarah Filippa Giardina, Donald Bergstrom, Lee Daniel Arnold
  • Compositions and methods for repelling blood-sucking and biting insects, ticks and mites
    Patent number: 9763444
    Abstract: Chromene derivatives based on a chromene amide isolated from Amyris texana. Also disclosed are compositions containing chromene derivatives (synthetic or natural) based on a chromene amide isolated from Amyris texana. Also methods for repelling blood-sucking and biting insects, ticks and mites involving treating (or exposing) an object (e.g., mammals such as humans) or area (e.g., a surface such as human skin) with a blood-sucking and biting insects, ticks and mites repelling effective amount of at least one compound selected from chromene derivatives (synthetic or natural) based on a chromene amide isolated from Amyris texana.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 19, 2017
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Kumudini M. Meepagala, Ulrich R. Bernier
  • Synthetic triterpenoids and methods of use in the treatment of disease
    Patent number: 9757359
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: September 12, 2017
    Assignees: REATA PHARMACEUTICALS, INC., TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
  • Bi-cyclo aldehyde as perfuming ingredient
    Patent number: 9752096
    Abstract: The present invention relates to the field of perfumery and provides certain bi-cyclo derivatives of formula (I) wherein R1 represents a hydrogen atom or a C1-2 alkyl group; R2 represents a hydrogen atom or a methyl group; and A represents a group of formula C3-5 alkanediyl group; at least one of said R1 or R2 represents a group containing at least one carbon atom. The compounds are in the form of a E or Z isomer or of a mixture thereof. These compounds are valuable perfuming ingredients capable of imparting lily of the valley and citrus notes to consumer products.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: September 5, 2017
    Assignee: Firmenich SA
    Inventor: Robert Moretti